---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-022588"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-24T00:00:13.180998+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aerovate Therapeutics reports Q2 net loss of $12.0M; cash runway into H2 2025

## Summary
- Net loss $12.0M in Q2 2022 vs $5.8M in Q2 2021; R&D expenses $8.4M, G&A $3.9M.
- Cash and investments $152.0M as of June 30, 2022; expected to fund operations into H2 2025.
- IMPAHCT Phase 2b/Phase 3 trial ongoing; topline Phase 2b data expected Q4 2023 or Q1 2024.
- Phase 1 data for AV-101 showed well-tolerated and reduced systemic exposure vs oral imatinib.
- Strengthened management: Stephen Yu joined as SVP Quality with 20+ years pharma experience.

## SEC filing metadata
- accession: 0001493152-22-022588
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000149315222022588/0001493152-22-022588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000149315222022588/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-022588
- JSON: https://secwatch.observer/filing/0001493152-22-022588.json
- Plain text: https://secwatch.observer/filing/0001493152-22-022588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.